Review article
On- and Off-Label Uses of Apremilast in Dermatology
Kerasia-Maria Plachouri
; Dermatology Department, University General Hospital of Patras, Patras, Greece
Sophia Georgiou
; Dermatology Department, University General Hospital of Patras, Patras, Greece
Abstract
Apremilast is an oral small-molecule phosphodiesterase 4
inhibitor with a multilevel immunomodulating mechanism of action.
It has received approval in many countries for the use in moderate-tosevere
plaque psoriasis and active psoriatic arthritis in adults. Herein,
we review the literature concerning the use of apremilast in dermatology,
with a focus on both the on- and the off-label uses of this medication
in dermatologic conditions. This paper is a systematic overview of
all the reported uses of apremilast in dermatology described in the literature
so far and was conducted according to the PRISMA Guidelines
for systematic reviews. There are several original articles, case series
and case reports In the literature that present either encouraging or
less promising results concerning the efficacy and safety of apremilast
in numerous inflammatory dermatological diseases. Despite the
potential effectiveness of apremilast in various indications, however,
randomized clinical trials on larger patient cohorts and with long-term
follow-up are necessary in order to adequately establish the role of
apremilast in dermatology overall.
Keywords
apremilast, dermatology, indications
Hrčak ID:
281294
URI
Publication date:
16.9.2020.
Visits: 329 *